Xomolix 2,5 mg/ml raztopina za injiciranje スロベニア - スロベニア語 - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

xomolix 2,5 mg/ml raztopina za injiciranje

chiesi pharmaceuticals gmbh - droperidol - raztopina za injiciranje - droperidol 2,5 mg / 1 ml - droperidol

Firmagon 欧州連合 - スロベニア語 - EMA (European Medicines Agency)

firmagon

ferring pharmaceuticals a/s - degareliks - prostatične neoplazme - endokrini terapija - firmagon is a gonadotrophin releasing hormone (gnrh) antagonist indicated:- for treatment of adult male patients with advanced hormone-dependent prostate cancer. - for treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy. - as neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone dependent prostate cancer.

Revasc 欧州連合 - スロベニア語 - EMA (European Medicines Agency)

revasc

canyon pharmaceuticals ltd. - desirudin - venska tromboza - antitrombotična sredstva - preprečevanje globoke venske tromboze pri bolnikih, ki so v postopku izbirnega kirurškega substitucijskega kolka ali kolena.

Entecavir Mylan 欧州連合 - スロベニア語 - EMA (European Medicines Agency)

entecavir mylan

mylan pharmaceuticals limited - entekavir monohidrat - hepatitis b - antivirusi za sistemsko uporabo - entecavir mylan is indicated for the treatment of chronic hepatitis b virus (hbv) infection in adults with:compensated liver disease and evidence of active viral replication, persistently elevated serum alanine aminotransferase (alt) levels and histological evidence of active inflammation and/or fibrosis. decompensated bolezen jeter. za obe nadomestilo in decompensated bolezni jeter, ta navedba temelji na kliničnem preskušanju podatkov v nucleoside naivnih bolnikov z hbeag pozitivnih in hbeag negativnih hbv okužbe. glede bolnikov z lamivudinom neodzivnega hepatitisa b. entecavir mylan je prav tako primerna za zdravljenje kronične hbv okužbe v nucleoside naivno pediatričnih bolnikih od 2 do.

Pedmarqsi 欧州連合 - スロベニア語 - EMA (European Medicines Agency)

pedmarqsi

fennec pharmaceuticals (eu) limited - sodium thiosulfate - ear diseases; ototoxicity - vsi drugi terapevtski izdelki - pedmarqsi is indicated for the prevention of ototoxicity induced by cisplatin chemotherapy in patients 1 month to < 18 years of age with localised, non-metastatic, solid tumours.